KR20180119961A - Cosmetic composition comprising mortierella oil - Google Patents
Cosmetic composition comprising mortierella oil Download PDFInfo
- Publication number
- KR20180119961A KR20180119961A KR1020170053742A KR20170053742A KR20180119961A KR 20180119961 A KR20180119961 A KR 20180119961A KR 1020170053742 A KR1020170053742 A KR 1020170053742A KR 20170053742 A KR20170053742 A KR 20170053742A KR 20180119961 A KR20180119961 A KR 20180119961A
- Authority
- KR
- South Korea
- Prior art keywords
- cosmetic composition
- skin
- oil
- mortierella
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 239000002537 cosmetic Substances 0.000 title claims abstract description 33
- 241000235575 Mortierella Species 0.000 title description 65
- 230000037303 wrinkles Effects 0.000 claims abstract description 32
- 108010035532 Collagen Proteins 0.000 claims abstract description 28
- 102000008186 Collagen Human genes 0.000 claims abstract description 28
- 229920001436 collagen Polymers 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 26
- 230000037394 skin elasticity Effects 0.000 claims abstract description 25
- 235000013376 functional food Nutrition 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 241000306282 Umbelopsis isabellina Species 0.000 claims abstract description 9
- 239000003921 oil Substances 0.000 claims description 75
- 230000006872 improvement Effects 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 1
- 235000019341 magnesium sulphate Nutrition 0.000 claims 1
- 230000000475 sunscreen effect Effects 0.000 claims 1
- 239000000516 sunscreening agent Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 abstract description 26
- 206010061218 Inflammation Diseases 0.000 abstract description 18
- 230000007794 irritation Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 73
- 210000003491 skin Anatomy 0.000 description 41
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 30
- 238000000034 method Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 102000016942 Elastin Human genes 0.000 description 6
- 108010014258 Elastin Proteins 0.000 description 6
- 229920002549 elastin Polymers 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036252 glycation Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- -1 powdered foundations Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 4
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 241000208467 Macadamia Species 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- 244000044822 Simmondsia californica Species 0.000 description 3
- 235000004433 Simmondsia californica Nutrition 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000010495 camellia oil Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000010773 plant oil Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229910000063 azene Inorganic materials 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229960000333 benzydamine Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229960004369 flufenamic acid Drugs 0.000 description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Botany (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 모르티에렐라 오일을 포함하는 화장료 조성물에 관한 것으로서, 보다 상세하게는 모르티에렐라 이사벨리나(Mortierella isabellina) 배양액으로부터 추출한 오일을 포함하는, 피부 탄력 증진, 주름 개선 또는 피부 트러블 개선에 있어 우수한 효과를 갖는 화장료 조성물에 관한 것이다. 또한, 본 발명은 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 건강기능식품 조성물 및 의약외품 조성물에 관한 것이다.The present invention relates to a cosmetic composition comprising Mortierella oil, and more particularly to a cosmetic composition comprising Mortierella < RTI ID = 0.0 > The present invention relates to a cosmetic composition having an excellent effect on skin elasticity enhancement, wrinkle improvement or skin trouble improvement, which comprises an oil extracted from an isabellina culture. The present invention also relates to a health functional food composition and a quasi-drug composition comprising an oil extracted from a culture medium of Mortierella canisella.
콜라겐(Collagen)은 피부의 섬유아세포(Fibroblast)에서 생성되는 주요 기질 단백질로서 세포 외 간질에 존재하고, 중요한 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포접착의 지탱, 세포 분할과 분화(유기체의 성장 혹은 상처 치유 시)의 유도 등이 알려져 있다. 이러한 콜라겐은 연령 및 자외선 조사에 의한 광 노화에 의해 감소하며, 콜라겐을 분해하는 콜라게나제(Collagenase) 효소 활성으로 콜라겐 감소가 촉진된다. 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다. 또한, 콜라겐 섬유는 진피층 내의 수분 보유에 중요한 역할을 하는 기질 단백질로 이러한 기질 단백질이 수분을 흡착하며, 이들이 이루는 구조 내부에 수분 보유력을 높여 피부가 적정 수분을 함유한 상태를 유지할 수 있도록 해주며, 이를 통해 피부의 탄력을 유지하는데 관여한다고 알려져 있다.Collagen is a major substrate protein produced in the fibroblast of skin and exists in extracellular epilepsy. Its important functions are mechanical rigidity of skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, And the induction of division and differentiation (at the time of organ growth or wound healing) are known. Such collagen is reduced by age and ultraviolet light irradiation, and collagenase activity, which degrades collagen, promotes collagen reduction. This is known to be closely related to the formation of wrinkles in the skin. In addition, collagen fiber plays an important role in water retention in the dermis. This protein absorbs water and enhances water retention in the structure of the collagen fiber, which enables the skin to maintain proper moisture content. It is known to be involved in maintaining the elasticity of the skin.
한편, 엘라스틴(Elastin) 섬유는 콜라겐과 가교 결합을 형성하며 피부 탄력에 관여하고 있는 주름 생성에 중요한 피부 구성성분이다. 엘라스틴 섬유의 결핍과 응집, 엘라스틴 분해 효소인 엘라스타제(Elastase)의 활성도의 현격한 증가는 피부 주름 생성 요인 중의 하나로 밝혀지고 있다. 엘라스타제는 엘라스틴을 분해할 수 있는 유일한 효소로서 이에 대한 저해는 피부 주름을 근본적으로 줄여줄 수 있다고 알려져 있다.On the other hand, Elastin fiber forms a cross-link with collagen and is a skin component that is important for wrinkle formation which is involved in skin elasticity. The deficiency and aggregation of elastin fibers and the dramatic increase in the activity of the elastin degrading enzyme Elastase have been found to be one of the causes of skin wrinkles. Elastase is the only enzyme capable of degrading elastin, and its inhibition is known to be able to radically reduce skin wrinkles.
아울러, 콜라겐 및 엘라스틴 섬유는 진피층 내의 수분 보유에 중요한 역할을 하는 기질 단백질로 이러한 기질 단백질이 수분을 흡착하며, 이들이 이루는 구조 내부에 수분 보유력을 높여 피부가 적정 수분을 함유한 상태를 유지할 수 있도록 해주며, 이를 통해 피부의 탄력을 유지하는데 관여한다고 알려져 있다.In addition, collagen and elastin fibers are substrate proteins that play an important role in moisture retention in the dermal layer. These protein proteins adsorb moisture and increase the water holding capacity inside the structure to maintain the skin's proper moisture content. And it is known to be involved in maintaining the elasticity of the skin.
현재, 피부 탄력 증진 및 주름 개선 화장료로는 레티노이드, 아데노신, 동물 태반 유래 단백질, 클로렐라 추출물 등이 알려져 있다. 가장 잘 알려져 있는 레티놀은 콜라겐 합성을 촉진하며 엘라스타제 효소를 저해하는 물질이지만 불안정하며, 피부 적용 시 자극, 발적 등의 안전성 문제로 사용량의 제한이 있으며, 클로렐라 추출물 등은 효과가 미미하여 실질적으로 피부 탄력 증진 및 주름 개선 효과를 기대하기가 어렵다고 알려져 있다.At present, retinoids, adenosine, animal placenta-derived proteins, chlorella extract, and the like are known as cosmetics for improving skin elasticity and improving wrinkles. The best known retinol promotes collagen synthesis and is a substance that inhibits elastase enzyme, but it is unstable. When applied to the skin, there is a limitation in usage due to safety problems such as irritation and redness, and chlorella extract has little effect, It is known that it is difficult to expect the effect of improving elasticity and wrinkle.
염증 반응은 붉어짐(feeling of redness), 따끔거림(pricking feeling), 화끈거림(burning hotness), 팽윤(swelling), 조직의 변화와 같은 5가지 현상으로 나타나는데, 이는 해로운 주위 환경, 즉 세균과 같은 외부 물질의 침입과 기계적 손상으로부터 생체를 보호하려는 생리적인 반응이다. 이러한 염증 현상은 여러 종류의 다형핵 백혈구(PMNs)와 면역 물질의 많은 증가를 초래하며, 이처럼 증가된 세포들은 염증성 세포 산물인 다양한 종류의 단백질 분해 효소와 사이토카인 등을 분비함으로써 치료 및 방어를 할 수 있게 해준다. 그러나, 이러한 작용은 인접해 있는 조직 세포와 비세포 성분들에 해로운 손상을 일으키기도 하며, 자외선이나 활성산소, 자유라디칼 등의 산화적 스트레스 등이 염증성 인자를 활성화시켜 각종 질병 및 피부의 노화를 일으킨다. 따라서, 적절한 조건 하에서는 염증 초기 상태가 지난 후 정상 기능을 되찾게 되지만, 염증을 자극하는 자극제가 없어지지 않거나 계속해서 만들어질 경우에는 결과적으로 만성 염증이 일어나게 되어 더욱더 심각한 조직의 손상을 가져온다.Inflammation reactions are manifested in five phenomena, such as feeling of redness, pricking feeling, burning hotness, swelling, and tissue changes, which may be caused by harmful environmental conditions, It is a physiological reaction to protect a living body from intrusion and mechanical damage. These inflammatory phenomena lead to a large number of polymorphonuclear leukocytes (PMNs) and immune substances, and these increased cells secrete a variety of inflammatory cell products, proteases and cytokines. I can do it. However, such action may cause harmful damage to adjacent tissue cells and non-cellular components, and oxidative stress such as ultraviolet rays, free radicals, and free radicals may activate inflammatory factors and cause aging of various diseases and skin . Therefore, under proper conditions, the normal function is restored after the initial state of inflammation. However, if irritant stimulating agents are not eliminated or continuously produced, chronic inflammation occurs as a result, resulting in more serious tissue damage.
한편, 염증을 소실시키기 위해 염증원의 제거, 생체 반응 및 증상을 감소시키는 작용을 하는 물질을 항염제라 한다. 현재까지 항염의 목적으로 이용되고 있는 물질로는 비스테로이드계로 플루페나믹산(flufenamic acid), 이부프로펜(ibuprofen), 벤지다민(benzydamine), 인도메타신(indomethacin)등이 있고 스테로이드 계통으로 프레드니솔론(prednisolone), 덱사메타손(dexamethasone) 등이 있다. 또한, 알란토인, 아즈엔, 하이드로코티손 등이 항염증에 효과가 있는 것으로 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 염증 완화 효과를 기대할 수 없는 문제점이 있다.On the other hand, a substance that acts to eliminate inflammation and to reduce vital signs and symptoms to eliminate inflammation is called an anti-inflammatory agent. To date, there have been a number of nonsteroidal anti-inflammatory agents, including flufenamic acid, ibuprofen, benzydamine, indomethacin, prednisolone, , Dexamethasone, and the like. It is also known that allantoin, azene, hydrocortisone and the like are effective for antiinflammation. However, these materials are limited in their use due to safety of skin, .
당화(Glycation)는 일반적으로 효소의 관여 없이 일어나는 단백질 또는 지방에 포도당 또는 과당과 같은 단순당이 공유결합을 형성하는 반응을 의미한다. 최종 당화산물의 축적은 단백질을 단단하고 더욱 부서지기 쉬운 상태로 변화시키며, 당화된 콜라겐은 진피층의 세포 외 기질에서 콜라겐이 적절한 구조를 형성하지 못하도록 함으로써 피부의 탄력을 잃게 하고 주름 생성을 촉진한다(Dyer, D. G. et al, The Journal of Clinical Investigation., 9, p. 2463, 1993). 또한 당화로 인해 생성된 최종 당화산물은 갈색 빛을 띠는 물질로써, 피부 노화가 진행되면서 점차 얼굴빛이 노랗게 변하는 원인 물질로 생각되고 있으며, 특정 최종 당화산물이 쌓일수록 피부에서 반사되는 반사 빛이 줄어든다고 알려져 있다. (Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009) 당화를 억제하는 물질로 아미노구아니딘(Aminoguanidine), 피리독사민(Pyridoxamine), 아스피린(Aspirin) 등이 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 효과를 기대할 수 없는 문제점이 있다.Glycation generally refers to a reaction in which a simple sugar such as glucose or fructose forms a covalent bond to a protein or fat that occurs without involvement of the enzyme. The accumulation of the final glycation product converts the protein into a harder and more brittle state, and the glycated collagen prevents the collagen from forming a proper structure in the extracellular matrix of the dermal layer, thereby losing skin elasticity and promoting wrinkle formation Dyer, DG et al, The Journal of Clinical Investigation, 9, p. 2463, 1993). In addition, the final saccharification product produced by the saccharification is a brownish substance, which is considered to be a cause of yellowing of the face gradually as the skin ages, and as the specific final saccharification product accumulates, the reflection light reflected from the skin is reduced . (Aminoguanidine, Pyridoxamine, Aspirin, etc.) have been known as inhibitors of glycation. However, they have been known to inhibit glycation, There is a problem that the use amount of the substance is limited due to the safety of the skin, or the effect is insignificant so that the effect can not be expected substantially.
이러한 배경하에, 본 발명자들은 천연에 존재하는 천연 자원들로부터 피부 탄력 증진, 주름 개선 또는 피부 트러블 개선에 있어 효과가 우수한 물질에 관하여 연구를 수행하였으며, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일이 피부에 자극을 주는 문제가 없으면서도 콜라겐 합성촉진, 항염 및 항당화 효과를 나타냄을 규명하여, 이를 활용한 화장료 조성물, 건강기능식품 조성물 및 의약외품 조성물을 완성하기에 이르렀다.Under these circumstances, the inventors of the present invention conducted studies on substances having excellent effects on skin elasticity enhancement, wrinkle improvement or skin trouble improvement from natural natural resources, and the oil extracted from the culture medium of Mortierella canisellina The present invention has been completed to provide a cosmetic composition, a health functional food composition, and a quasi-drug composition utilizing the same, without causing a problem of irritation and promoting collagen synthesis, anti-inflammation and antagonism.
본 발명의 목적은 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 화장료 조성물을 제공하는 것이다.It is an object of the present invention to provide a cosmetic composition comprising an oil extracted from a culture medium of Mortierella canisella as an active ingredient.
구체적으로, 본 발명의 목적은 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물을 제공하는 것이다. Specifically, the object of the present invention is to provide a cosmetic composition for skin elasticity enhancement or wrinkle improvement comprising an oil extracted from a culture medium of Mortierella canisella as an active ingredient.
또한 구체적으로, 본 발명의 목적은 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 피부 트러블 개선용 화장료 조성물을 제공하는 것이다.More specifically, the object of the present invention is to provide a cosmetic composition for improving skin troubles comprising an oil extracted from a culture medium of Mortierella canisella as an active ingredient.
본 발명의 다른 목적은 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition containing an oil extracted from a culture medium of Mortierella canisella as an active ingredient.
본 발명의 또 다른 목적은 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 의약외품 조성물을 제공하는 것이다.It is still another object of the present invention to provide a quasi-drug composition comprising an oil extracted from a culture medium of Mortierella canisella as an active ingredient.
본 발명은 상기와 같은 과제들을 해결하고, 본 발명의 목적을 달성하기 위하여 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 화장료 조성물을 제공한다.In order to solve the above-mentioned problems, the present invention provides a cosmetic composition comprising an oil extracted from a culture medium of Mortierella canisella as an active ingredient to achieve the object of the present invention.
구체적으로, 본 발명의 하나의 양태로서, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물을 제공한다.Specifically, as one embodiment of the present invention, there is provided a cosmetic composition for skin elasticity enhancement or wrinkle improvement comprising an oil extracted from a culture solution of Mortierella canisella as an active ingredient.
구체적으로, 본 발명의 다른 하나의 양태로서, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 피부 트러블 개선용 화장료 조성물을 제공한다.Specifically, as another embodiment of the present invention, there is provided a cosmetic composition for improving skin trouble comprising an oil extracted from a culture solution of Mortierella canisella as an active ingredient.
또한, 본 발명의 또 다른 하나의 양태로서, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 건강기능식품 조성물을 제공한다. According to still another aspect of the present invention, there is provided a health functional food composition containing an oil extracted from a culture medium of Mortierella canisella as an active ingredient.
또한, 본 발명의 또 다른 하나의 양태로서, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 유효성분으로 포함하는 의약외품 조성물을 제공한다. According to still another aspect of the present invention, there is provided a quasi-drug composition comprising an oil extracted from a culture medium of Mortierella canisella as an active ingredient.
이하 본 발명을 구체적으로 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에서는 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 화장료 조성물을 제공한다.The present invention provides a cosmetic composition comprising an oil extracted from a culture medium of Mortierella canisella.
본 발명의 모르티에렐라 이사벨리나(Mortierella isabellina)는 모르티에렐라(Mortierella)목 모르티에렐라과에 속하는 진균류의 미생물이다. 모르티에렐라 종은 일반적으로 식물, 동물 및 인간에게 병원성이 없는 종에 해당한다. The Mortierella < RTI ID = 0.0 > isabellina ) is a microorganism of fungi belonging to the family Mortierella thymothierella. Mortierella species are generally species that are not pathogenic to plants, animals and humans.
본 발명에 있어서 "모르티에렐라 오일"은 모르티에렐라 이사벨리나 (Mortierella isabellina)를 배양하여 얻은 오일이다. 보다 구체적으로, 모르티에렐라 오일은 미생물 유래 오일로서, 화장료의 성분 중 수분증발차단제로 사용되는 것으로 알려져 있다. 상기 모르티에렐라 오일의 획득 방법에 특별히 한정되지 않으며, 당업계에 공지된 방법으로 제조하거나, 시판되는 물질을 사용할 수 있다.In the present invention, " Mortierella oil " is an oil obtained by culturing Mortierella isabellina . More specifically, it is known that Mortierella oil is used as a moisture-blocking agent in cosmetic ingredients as a microbial-derived oil. The method for obtaining the above-mentioned Mortierella oil is not particularly limited, and it may be prepared by a method known in the art, or a commercially available substance may be used.
본 발명의 일 실시예에서는, 허브 혼합물을 첨가하고, 모르티에렐라 이사벨리나(Mortierella isabellina)를 접종하여 240시간 동안 배양한 후, 배양액을 여과하여 배양액과 균체를 분리하고, 클로로포름과 메탄올로 이루어진 추출용매로 농축물(유지)을 추출하였다. 상기 농축물을 냉장 및 냉동 온도에서 보관하여 고체상과 액체상으로 유지를 물리적으로 분리하는 탈납 공정; 상기 유지에서 검 상태 물질 및 불순물을 제거하는 탈검 공정; 잔류되어 있는 유용성 색소물질을 흡착하여 제거하는 탈색 및 탈취 공정을 거치고 정제하여, 최종적으로 모르티에렐라 오일을 수득하였다.In one embodiment of the present invention, a herbal mixture is added and cultured for 240 hours inoculated with Mortierella isabellina . Then, the culture solution is separated by filtration to separate the culture medium and cells, and extraction with chloroform and methanol The concentrate (oil) was extracted with a solvent. A dewaxing process for physically separating the concentrate into a solid phase and a liquid phase by storing the concentrate at a refrigeration and freezing temperature; A deblocking step of removing gum-like materials and impurities from the oil; Followed by a decolorization and deodorization process for adsorbing and removing the remaining usable coloring matter substance, and finally, a Mortierella oil was finally obtained.
본 발명에 있어서 "배양"은 미생물을 적당히 인공적으로 조절한 환경조건에서 생육시키는 것을 의미한다. 또한, 본 발명의 "배양액"은 미생물을 배양한 결과물로서 얻어진 물질을 의미한다. In the present invention, " cultivation " means that microorganisms are grown under moderately artificially controlled environmental conditions. The "culture solution" of the present invention means a substance obtained as a result of culturing a microorganism.
본 발명에서 배양 방법은 당업계에 알려져 있는 방법을 통해 수행될 수 있으나, 구체적으로 기포(Air bubble)를 통한 배양 방법일 수 있고, 여기에 한정되는 것은 아니다. 본 발명의 일 실시예에서는, 허브 혼합물 및 모르티에렐라 이사벨리나(Mortierella isabellina)의 종 배양액(Seed culture)을 첨가하고, 기포를 통한 본 배양(main culture)을 진행하여 모르티에렐라 이사벨리나 배양액을 수득하였다.In the present invention, the culture method may be performed by a method known in the art, but it may be a method of culturing through air bubbles, but is not limited thereto. In one embodiment of the present invention, a herbal mixture and a seed culture of Mortierella isabellina are added and the main culture is carried out through bubbles to obtain a culture medium of Mortierella isabellina .
본 발명의 "발효액"은 허브 혼합물을 첨가하여 모르티에렐라 이사벨리나의 발효 과정을 통해 얻어진 물질로서, 본 발명에 있어서 상기 배양액과 동일한 의미로 사용될 수 있다. 상기의 용어 "발효"는 미생물이 가지고 있는 효소를 이용하여 유기물을 분해시키는 것을 의미한다. 보다 구체적으로, 좁은 의미로 미생물이 산소를 사용하지 않고 에너지를 얻는 당 분해과정을, 넓은 의미로는 미생물이나 균류 등을 이용해 인간에게 유용한 물질을 얻어내는 과정을 의미한다.The " fermentation broth " of the present invention is a substance obtained through fermentation process of Mortierella canisella by adding a herbal mixture, and can be used in the same sense as the culture broth in the present invention. The term " fermentation " as used above means to decompose an organic substance using an enzyme possessed by the microorganism. More specifically, it refers to a process in which a microorganism obtains energy without using oxygen in a narrow sense, and in a broad sense, obtains substances useful to humans by using microorganisms or fungi.
본 발명에 있어서 "추출물"은 모르티에렐라 이사벨리나의 배양액을 여과하여 균체를 분리하고, 추출 용매로 추출처리 하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.In the present invention, the term "extract" means an extract obtained by filtering a culture solution of Mortierella isolella or the like to separate cells and extracting the extract with an extraction solvent, a diluted solution or a concentrate of the extract, a dried product obtained by drying the extract, An extract of the formulation itself, and an extract of all the formulations which can be formed using the extract, such as a controlled preparation or a purified product, or a mixture thereof.
본 발명의 상기 모르티에렐라 이사벨리나의 배양액 등의 추출에 있어서, 상기 추출물을 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2종 이상의 방법을 병용하여 수행될 수 있다.The method for extracting the above-mentioned extract in the culture of the above-mentioned Mortierella isolella of the present invention is not particularly limited and may be carried out according to a method commonly used in the art. Non-limiting examples of the extraction method include hydrothermal extraction, ultrasonic extraction, filtration, and reflux extraction. These may be performed alone or in combination with two or more methods.
본 발명에서 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 C1 내지 C4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 클로로포름 등의 유기용매; 또는 이들의 혼합물을 사용할 수 있으며, 바람직하게, 물, 저급알코올, 1,3-부틸렌글리콜, 에틸아세테이트를 단독으로 사용하거나 2종 이상 혼합하여 사용할 수 있다. The kind of the extraction solvent in the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water; C1 to C4 lower alcohols such as methanol, ethanol, propyl alcohol and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol and propylene glycol; And hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; An organic solvent such as chloroform; Or a mixture thereof. Water, lower alcohol, 1,3-butylene glycol, and ethyl acetate may be used alone or in admixture of two or more.
본 발명의 일 실시예에서는 클로로포름과 메탄올로 이루어진 추출용매를 사용하여 모르티에렐라 이사벨리나 배양액의 농축물(유지)을 추출하였다.In one embodiment of the present invention, a concentrate (oil) of the culture medium of Mortierella canisella was extracted using an extraction solvent consisting of chloroform and methanol.
본 발명의 "오일"은 식물성, 광물성 또는 동물성 오일을 함유한 화장료 조성물의 하나로서, 구체적으로 페이스 오일을 의미할 수 있다. 상기 용어 오일은 본 발명에 있어서 "발효 오일"과 동일한 의미로 사용될 수 있다. &Quot; Oil " of the present invention is one of cosmetic compositions containing vegetable, mineral or animal oil, and may specifically mean face oil. The term oil may be used interchangeably with " fermented oil " in the present invention.
본 발명에 있어서 "피부 탄력 증진"이란 피부가 쳐지거나 늘어지는 정도를 완화시켜주는 것으로, 엘라스틴으로 구성된 탄력섬유가 콜라겐(collagen)이라고 하는 교원섬유와 함께 존재하는데, 엘라스틴과 콜라겐이 충분히 존재하는 상태에서 피부 탄력이 유지되는 것을 말한다.In the present invention, " skin elasticity enhancement " is intended to alleviate the degree to which the skin is stained or stretched. Elastic fibers composed of elastin are present together with collagen fibers called collagen, The skin elasticity is maintained.
본 발명에 있어서 "주름 개선"이란 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다. In the present invention, " improvement of wrinkles " refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating already formed wrinkles.
본 발명의 일 실험예에서는, 모르티에렐라 오일의 콜라겐 합성 촉진 효과를 확인하기 위해, 콜라겐 합성률을 확인하였다. 그 결과, 모르티에렐라 오일을 첨가한 실험군의 경우 대조군과 비교해 우수한 콜라겐 합성률을 나타내었다(표 1). 이를 통해 본 발명의 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 조성물은 피부 탄력 증진 또는 주름 개선 용도로 사용될 수 있음을 확인하였다.In one experimental example of the present invention, in order to confirm the promoting effect of collagen synthesis of Mortierella oil, collagen synthesis rate was confirmed. As a result, the experimental group containing Mortierella oil showed excellent collagen synthesis ratio as compared with the control group (Table 1). Thus, it was confirmed that the composition comprising the oil extracted from the culture medium of Mortierella canisella of the present invention can be used for skin elasticity enhancement or wrinkle improvement.
본 발명에 있어서 "피부 트러블"이란 대식세포에서의 과도한 일산화질소 생성으로 인하여 유발된 염증에 의해 발생할 수 있는 피부질환을 의미한다. 상기 피부 트러블은 염증과 관련된 피부질환이면 그 종류에 관계없이 모두 포함되며, 상기 염증과 관련된 피부질환의 비제한적인 예로는 아토피 피부염, 건선, 방사선, 화학물질, 화상 등에 의해 촉발되는 홍반성 질환, 산 화상, 수포성 피부병, 태선 모양 종류 질환, 알레르기에 기한 가려움증, 지루성 습진, 장미 여드름, 심상성 천포창, 다형 삼출성 홍반, 결절 홍반, 귀두염, 음문염, 원형 탈모증과 같은 염증성 모발 손실, 피부 T-세포 림프종 등이 있으며, 구체적으로, 피부발진, 여드름, 뾰루지, 주사(빨간 코) 등이 있으나 이에 제한되는 것은 아니다. In the present invention, " skin trouble " means a skin disease which may be caused by inflammation caused by excessive nitric oxide production in macrophages. The skin trouble includes all kinds of skin diseases related to inflammation regardless of the type thereof. Non-limiting examples of the skin diseases related to the inflammation include inflammatory diseases caused by atopic dermatitis, psoriasis, radiation, chemical substances, Inflammatory hair loss such as acid burns, watery skin diseases, psoriasis type diseases, allergic itching, seborrheic eczema, rose acne, pemphigus vulgaris, polymorphic exudative erythema, erythema nodosum, Cell lymphoma, and the like. Specific examples include skin rash, acne, rash, injection (red nose), but are not limited thereto.
또한, 본 발명에 있어서 "피부 트러블 개선"이란 피부에 트러블이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 트러블을 완화시키는 것을 말한다.In the present invention, " improvement of skin troubles " refers to inhibiting or inhibiting the generation of troubles in the skin, or alleviating troubles already generated.
본 발명에 있어서 "항염"이란 염증을 억제하는 것을 말하며, 상기 염증은 어떤 자극에 대한 생체조직의 방어반응의 하나로, 조직 변질, 순환 장애와 삼출, 조직 증식의 세 가지를 병발하는 복잡한 병변을 말한다. 보다 구체적으로 염증은 선천성 면역의 일부이며 다른 동물에서처럼 인간의 선천성 면역은 병원체에 특이적으로 존재하는 세포 표면의 패턴을 인식한다. 식세포는 그런 표면을 가진 세포를 비자기로 인식하고 병원체를 공격한다. 만일 병원균이 신체의 물리적 장벽을 깨고 들어온다면 염증반응이 일어난다. 염증반응은 상처부위에 침입한 미생물들에 대해 적대 환경을 만드는 비특이적인 방어작용이다. 염증반응에서, 상처가 나거나 외부 감염체가 체내로 들어왔을 때, 초기단계 면역반응을 맡고 있는 백혈구들이 몰려들어 사이토카인을 발현한다. 따라서 세포 내 사이토카인의 발현양이 염증반응 활성화의 지표가 된다. 본 발명의 항염증은 피부에서 발병된 염증을 억제하는 것일 수 있다.In the present invention, " anti-inflammation " refers to inhibition of inflammation. The inflammation refers to a complex lesion involving tissue degeneration, circulatory disturbance, exudation, and tissue proliferation, . More specifically, inflammation is part of congenital immunity and, like in other animals, human congenital immunity recognizes a pattern of cell surfaces that are specifically present in a pathogen. Phagocytes recognize cells with such surfaces as non-magnetic and attack pathogens. If pathogens break through the physical barriers of the body, an inflammatory reaction occurs. Inflammation is a nonspecific defense that creates hostile environments for microorganisms entering the wound area. In the inflammatory response, white blood cells that are responsible for the early stage of immune response, when wounded or infected, enter the body to express cytokines. Therefore, the expression level of intracellular cytokine is an index of inflammatory response activation. The antiinflammation of the present invention may be to suppress inflammation caused in the skin.
본 발명의 일 실험예에서는, 모르티에렐라 오일의 항염증 효과를 확인하기 위해, 산화질소(NO) 생성 저해효능을 확인하였다. 그 결과, 모르티에렐라 오일을 첨가한 실험군의 경우 대조군과 비교해 우수한 NO 생성 저해율 및 항염 효과를 나타내었다(표 2). 이를 통해 본 발명의 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 조성물은 피부 트러블 개선 용도로 사용될 수 있음을 확인하였다.In one experimental example of the present invention, in order to confirm the antiinflammatory effect of Mortierella oil, nitric oxide (NO) production inhibitory effect was confirmed. As a result, the experimental group to which Mortierella oil was added showed an excellent inhibitory effect on NO production and anti-inflammatory effect as compared with the control group (Table 2). Thus, it was confirmed that the composition containing the oil extracted from the culture medium of Mortierella isolella of the present invention can be used for improving skin troubles.
또한, 본 발명의 일 실험예에서는, 모르티에렐라 오일의 항당화 효과를 확인하기 위해, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 조성물을 비롯한 다양한 오일 시료의 당화 저해율을 측정하였다. 그 결과, 모르티에렐라 오일을 첨가한 실험군의 경우 대조군과 비교해 우수한 항당화 효과를 나타냄을 알 수 있었다(표 3). 이를 통해 본 발명의 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 조성물은 주름 개선 및 항염 등의 활성에 있어서 보조적인 역할로 작용하여 상승효과를 기대할 수 있음을 알 수 있었다.In order to confirm the antihalation effect of Mortierella oil in one experimental example of the present invention, the saccharification inhibition ratios of various oil samples including a composition containing oil extracted from a culture medium of Mortierella canisella were measured. As a result, it was found that the test group to which Mortierella oil was added exhibited an excellent antagonism effect as compared with the control group (Table 3). As a result, it was found that the composition containing the oil extracted from the culture medium of Mortierella canisella according to the present invention acts as an auxiliary role in the activities of improving wrinkles and anti-inflammation, and thus a synergistic effect can be expected.
본 발명의 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention can be used as a cosmetic composition in the form of a solution, an external ointment, a cream, a foam, a nutritional lotion, a softening longevity pack, a pack, The composition may be formulated into a formulation selected from the group consisting of solutions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powdered foundations, emulsion foundations, wax foundations, patches and sprays no.
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier to be incorporated in a general skin cosmetic composition, and examples thereof include oil, water, a surfactant, a moisturizer, A thickening agent, a chelating agent, a coloring matter, an antiseptic, a perfume, and the like may be appropriately compounded, but the present invention is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.The cosmetically acceptable carrier to be contained in the cosmetic composition of the present invention varies depending on the formulations.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the present invention is an ointment, a paste, a cream or a gel, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide Mixtures of these may be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as the carrier component, Propellants such as fluorohydrocarbons, propane / butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butyl glycol oil may be used, in particular fatty acid esters of cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycols or sorbitan may be used have.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.When the formulation of the present invention is a soap, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, glycerol, .
본 발명의 또 다른 양태로서, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 건강기능식품 조성물을 제공한다.In another aspect of the present invention, there is provided a health functional food composition comprising an oil extracted from a culture medium of Mortierella canisella.
구체적으로, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 피부탄력 증진, 주름개선 또는 피부 트러블 개선용 건강기능식품 조성물을 제공할 수 있다. "피부탄력 증진", "주름 개선" 및 "피부 트러블 개선"은 상기에서 설명한 바와 같다. Specifically, it is possible to provide a health functional food composition for enhancing skin elasticity, improving wrinkles or improving skin troubles comprising an oil extracted from a culture solution of Mortierella canisella. &Quot; skin elasticity enhancement ", " wrinkle improvement " and " skin trouble improvement "
본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 피부재생, 각질박리, 피부탄력 증진, 주름 개선 또는 피부 트러블 개선 효과를 증진시키기 위한 보조제로 섭취가 가능하다.In the present invention, the term " health functional food " refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body. The term "functional" as used herein means that the structure and function of the human body have a beneficial effect on health uses such as controlling nutrients or physiological actions. The health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art. In addition, the formulations of the above health functional foods may also be manufactured without limitations as long as they are acceptable as health functional foods. The food composition of the present invention can be manufactured in various formulations, and unlike general pharmaceuticals, it has an advantage of being free from side effects that may occur when a food is used as a raw material for a long period of time, and is excellent in portability. Health functional foods can be supplemented to improve skin rejuvenation, exfoliation, skin elasticity improvement, wrinkle improvement or skin trouble improvement effect.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 화학식 1로 표시되는 화합물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함한다.The form of the health functional food of the present invention is not limited, and may include all foods in the conventional meaning, and may be used in combination with terms known in the art such as functional foods. In addition, the health functional food of the present invention can be prepared by mixing other suitable auxiliary ingredients, which may be included in food, according to the selection of a person skilled in the art, and known additives. Examples of foods that can be added include dairy products including meats, sausages, breads, chocolates, candies, snacks, confectionery, pizza, ramen and other noodles, gums, ice creams, various soups, drinks, tea, Vitamin complex, and the like, and can be prepared by adding to juice, tea, jelly, juice and the like prepared by using the compound represented by the formula (1) according to the present invention as a main component. It also includes foods used as feed for animals.
본 발명의 또 다른 양태로서, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 의약외품 조성물을 제공한다.As another embodiment of the present invention, there is provided a quasi-drug composition comprising an oil extracted from a culture medium of Mortierella canisella.
구체적으로, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 피부탄력 증진, 주름개선 또는 피부 트러블 개선용 의약외품 조성물을 제공할 수 있다. "피부탄력 증진", "주름 개선" 및 "피부 트러블 개선"은 상기에서 설명한 바와 같다. Specifically, it is possible to provide a quasi-product composition for improving skin elasticity, improving wrinkles or improving skin troubles, which comprises an oil extracted from a culture solution of Mortierella canisella. &Quot; skin elasticity enhancement ", " wrinkle improvement " and " skin trouble improvement "
본 발명의 의약외품 조성물에는 상기 성분 외에 필요에 따라 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더욱 포함할 수 있다. 상기 약학적으로 허용 가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다.The quasi-drug composition of the present invention may further contain a pharmaceutically acceptable carrier, excipient or diluent as necessary in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as the effect of the present invention is not impaired, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, .
본 발명의 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사 가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 들 수 있다.Representative examples of the pharmaceutically acceptable carrier, excipient or diluent of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium Methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oils such as sodium carboxymethylcellulose, , Injectable ester, witepsol, macrogol, tween 61, cacao paper, and laurie paper.
또한, 본 발명의 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 상기 조성물을 의약외품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부 탄력 증진, 주름 개선, 보습, 또는 항염증 성분을 포함할 수 있을 것이다. 추가적인 피부 탄력 증진, 주름 개선, 보습, 또는 항염증 성분을 포함하게 되면 본 발명의 조성물의 피부 탄력 증진, 주름 개선, 보습, 또는 피부 트러블 개선 효과는 더욱 증가될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 상기 의약외품 조성물은 당업계에 공지된 당업계에 공지된 피부 탄력 증진, 주름 개선, 보습 또는 항염증 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베툴린산 및 클로렐라 추출물; 당업계에 공지된 항염증 성분으로서, 비스테로이드계로 플루페남산, 이부프로펜, 벤지다민, 인도메타신, 프레드니솔론, 덱사메타손, 알란토인, 아즈엔, 하이드로코티손; 및 이들의 유도체와 각종 식물 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 성분을 추가로 포함할 수 있다. 추가 성분은 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 피부 안전성, 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 조성물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.In addition, when the composition containing the oil extracted from the culture medium of the Mortierella canisella of the present invention is used as a quasi-drug, it may further contain one or more active ingredients exhibiting the same or similar functions. For example, it may contain known skin elasticity enhancement, wrinkle improvement, moisturizing, or anti-inflammatory ingredients. The skin elasticity enhancement, wrinkle enhancement, moisturizing, or skin trouble improvement effect of the composition of the present invention may be further increased if the skin elasticity enhancement, wrinkle improvement, moisturizing, or anti-inflammatory ingredient is further included. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. The quasi-drug composition includes retinoic acid, TGF, an animal placenta-derived protein, betulinic acid and chlorella extract, skin elasticity enhancement, wrinkle improvement, moisturizing or anti-inflammatory ingredients well known in the art; As anti-inflammatory ingredients known in the art, there are non-steroid based flufenamic acid, ibuprofen, benzydamine, indomethacin, prednisolone, dexamethasone, allantoin, azene, hydrocortisone; And derivatives thereof, and various plant extracts. ≪ Desc / Clms Page number 2 > The additional ingredients may be included in an amount of 0.0001% to 10% by weight based on the total weight of the composition, and the content ranges include skin safety, ease of formulation of a composition containing the oil extracted from the culture medium of Mortierella canisella, . ≪ / RTI >
본 발명의 의약외품 조성물은 소독 청결제, 샤워 폼, 연고액, 물티슈, 코팅제 등을 예시할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition of the present invention can be exemplified by a disinfectant cleaner, a shower foam, a softener solution, a wet tissue, a coating agent, and the like. The formulation method, dosage, usage method, And the like.
본 발명의 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 화장료 조성물은 피부 탄력 증진, 주름 개선 및 피부 트러블 개선 효능이 우수하다. 구체적으로, 본 발명의 조성물은 피부에 자극을 주는 문제가 없으면서도 콜라겐 합성촉진, 항염 및 항당화 효과가 우수하여 피부 탄력 증진, 주름 개선 및 피부 트러블 개선용 화장료 조성물로서 활용도가 높다. 또한, 본 발명의 모르티에렐라 이사벨리나 배양액으로부터 추출한 오일을 포함하는 조성물은 건강기능식품 조성물 및 의약외품 조성물로서 사용할 수 있다.The cosmetic composition comprising the oil extracted from the culture medium of the Mortierella canisella of the present invention is excellent in skin elasticity, wrinkle and skin troubles. Specifically, the composition of the present invention is highly effective as a cosmetic composition for promoting skin elasticity, wrinkle and skin trouble, without compromising skin irritation and promoting collagen synthesis, anti-inflammation and anti-glycation. In addition, the composition containing the oil extracted from the culture medium of Mortierella canisella of the present invention can be used as a health functional food composition and a quasi-drug composition.
이하, 실시예 및 실험예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예 및 실험예는 오로지 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들에 의해 제한되는 것은 아니다.Hereinafter, the constitution and effects of the present invention will be described in more detail with reference to Examples and Experimental Examples. These Examples and Experimental Examples are only for illustrating the present invention, but the scope of the present invention is not limited thereto.
실시예 1Example 1 : 모르티에렐라 오일의 제조: Preparation of Mortierella oil
허브 혼합물을 첨가하고, 모르티에렐라 이사벨리나(Mortierella isabellina)를 접종하여 240시간 동안 배양한 후, 배양액을 여과하여 배양액과 균체를 분리하고, 클로로포름과 메탄올로 이루어진 추출용매로 농축물(유지)을 추출하였다. 상기 농축물을 냉장 및 냉동 온도에서 보관하여 고체상과 액체상으로 유지를 물리적으로 분리하는 탈납 공정; 상기 유지에서 검 상태 물질 및 불순물을 제거하는 탈검 공정; 잔류되어 있는 유용성 색소물질을 흡착하여 제거하는 탈색 및 탈취 공정을 거치고 정제하여, 최종적으로 모르티에렐라 오일을 수득하였다.The herbal mixture was added and the Mortierella < RTI ID = 0.0 > isabellina ) and cultured for 240 hours. Then, the culture solution was filtered to separate the culture medium and the cells, and the concentrate (oil) was extracted with an extraction solvent composed of chloroform and methanol. A dewaxing process for physically separating the concentrate into a solid phase and a liquid phase by storing the concentrate at a refrigeration and freezing temperature; A deblocking step of removing gum-like materials and impurities from the oil; Followed by a decolorization and deodorization process for adsorbing and removing the remaining usable coloring matter substance, and finally, a Mortierella oil was finally obtained.
실험예 1 : 모르티에렐라 오일의 콜라겐 합성 촉진 효과 확인EXPERIMENTAL EXAMPLE 1 Confirmation of Collagen Synthesis Promotion Effect of Mortierella L. Oil
실시예 1의 모르티에렐라 오일의 콜라겐 합성 촉진 효과 확인을 위해, 모르티에렐라 오일을 비롯한 다양한 오일 시료를 농도별로 인간 진피 섬유 아세포(Human dermal fibroblast cell)에 24시간 동안 처리하고, procollagen typeC-peptide(PIP) EIA kit 법을 이용하여 콜라겐 합성 효과를 평가하였고, 하기의 수학식 1을 이용하여 콜라겐 합성률을 계산한 결과를 하기의 표 1에 나타내었다. 각 시료의 콜라겐 합성률은 무처리군의 콜라겐 합성률을 0%로 가정하였을 때 그에 대한 상대적인 값에 해당하며, 양성 대조군은 TGF-β 10ng/ml, 무처리군은 공시료(DMEM) 이다.In order to confirm the promoting effect of the collagen synthesis of the Mortierella oil of Example 1, various oil samples including Mortierella oil were treated for 24 hours in human dermal fibroblast cells by concentration, and the procollagen type C-peptide (PIP) EIA kit method, and the collagen synthesis rate was calculated using the following equation (1). The results are shown in Table 1 below. The collagen synthesis rate of each sample corresponds to the relative value when the collagen synthesis ratio of the untreated group is assumed to be 0%. The positive control group is TGF-β 10 ng / ml, and the untreated group is the blank sample (DMEM).
[수학식 1][Equation 1]
상기 표 1의 결과에서 볼 수 있듯이, 모르티에렐라 오일은 다른 식물 오일과 비교하였을 때, 동일한 농도에서 보다 우수한 콜라겐 합성률을 보였고, 따라서 모르티에렐라 오일은 우수한 콜라겐 합성 효과를 나타내어 피부 탄력 증진 또는 주름 개선에 있어 훨씬 더 뛰어난 효과를 기대할 수 있었다.As can be seen from the results of Table 1, Mortierella oil showed a better collagen synthesis rate at the same concentration as the other plant oils, and therefore, Mortierella oil showed excellent collagen synthesis effect, We were able to expect much better results in wrinkle improvement.
실험예Experimental Example 2 : 모르티에렐라 오일의 항염증 효과 확인 2: Identification of anti-inflammatory effect of Mortierella oil
상기 실시예 1의 모르티에렐라 오일의 항염증 효과를 확인하기 위해, 산화질소(NO)생성 저해효능을 확인하였다. 산화질소(NO) 생성 저해 효능은 RAW 264.7 macrophage에서 세포 외로 방출되는 산화질소(NO)의 생성 저해율을 통해 평가하였다. 모르티에렐라 오일을 비롯한 다양한 오일 시료를 농도별로 희석하여 LPS와 함께 세포에 처리하고 24시간 배양한 후 세포 배양액과 Griess reagent를 반응시켜 NO 생성을 측정하고, 하기의 수학식 2을 이용하여 NO 생성 저해율을 계산한 결과를 하기의 표 2에 나타내었다. 각 시료의 NO 생성 저해율은 음성 대조군의 NO 생성 저해율을 0%, 무처리군의 No 생성 저해율을 100%로 가정하였을 때 그에 대한 상대적인 값이며, 양성 대조군은 L-NMMA 20ppm, 음성 대조군은 LPS 1ppm, 무처리군은 공시료(DMEM)이다.In order to confirm the anti-inflammatory effect of Mortierella oil of Example 1, the inhibitory effect on NO production was confirmed. The inhibitory effect of nitric oxide (NO) production was evaluated by inhibiting the production of nitric oxide (NO) exocytically from RAW 264.7 macrophages. Various oil samples including Mortierella oil were diluted by concentration and treated with LPS for 24 hours. Then, NO production was measured by reacting the cell culture with Griess reagent, and NO production The inhibition rate was calculated and the results are shown in Table 2 below. The NO production inhibition rate of each sample was a relative value when the NO generation inhibition rate of the negative control group was 0% and the No generation inhibition rate of the untreated group was 100%. The positive control group was 20 ppm of L-NMMA and the negative control group was 1 ppm of LPS , And the untreated group is a blank sample (DMEM).
[수학식 2]&Quot; (2) "
상기 표 2의 결과에서 볼 수 있듯이, 모르티에렐라 오일은 대표적인 항염 의약물질인 L-NMMA와 비교하였을 때, 더 낮은 농도에서도 L-NMMA와 유사하게 우수한 NO 생성 저해율을 보였다. 따라서, 모르티에렐라 오일은 우수한 항염 효과를 나타내어, 다른 식물 오일과 비교하였을 때 피부 트러블 개선에 있어 훨씬 더 뛰어난 효과를 기대할 수 있었다.As can be seen from the results in Table 2 above, Mortierella oil showed an excellent inhibitory effect on NO production similar to that of L-NMMA even at a lower concentration as compared with L-NMMA, a representative anti-inflammatory drug. Therefore, Mortierella oil showed excellent anti-inflammatory effect, and it could be expected to have much better effect in improving skin troubles when compared with other plant oils.
실험예Experimental Example 3 : 모르티에렐라 오일의 3: of Mortierella oil 항당화Antialcification 효과 확인 Check the effect
실시예 1의 모르티에렐라 오일의 항당화 효과를 확인하기 위해, L-아르기닌(arginine)과 포도당을 이용하여 항당화 활성을 측정하였다. 먼저, 1M 인산 완충용액(pH 7.4)을 이용하여 1M L-아르기닌(arginine), 1M 포도당을 녹여 준비하고 1M 인산 완충용액을 이용하여 시료를 100ppm이 되도록 희석해서 준비하였다. 1M L-아르기닌과 1M 인산 완충용액을 1 대 4의 비율로 섞은 다음 96-웰 플레이트에 80㎕씩 분주하였다. 여기에 각각 100ppm으로 희석한 시료와 양성 대조군으로 사용될 0.01M 아미노구아니딘(aminoguanidin)을 100㎕씩 첨가하였다. 이 시료들을 잘 섞어준 다음, 마지막으로 포도당의 최종 농도가 0.1M이 되도록 1M 인산 완충용액으로 희석한 포도당을 넣은 후, 70 에서 4시간 동안 반응시켰다. 96-웰 플레이트를 분광 광도계를 이용하여 420nm에서 흡광도를 측정하여 당화 정도를 측정하였다. 하기 수학식 3의 당화(Glycation) 실험군은 1M L-아르기닌과 1M 포도당을 넣어 당화를 유발시킨 실험군이며, 시료 자체의 흡광도를 측정하기 위해서 포도당을 넣지 않고 1M L-아르기닌과 시료만을 넣어 420nm에서 흡광도를 측정하였다. 당화 저해 활성은 하기의 수학식 3을 이용해 계산하였으며, 그 결과는 하기 표 3에 나타내었다.In order to confirm the anticarious effect of the Mortierella oil of Example 1, antagonism activity was measured using L-arginine and glucose. First, 1 M L-arginine and 1 M glucose were dissolved in a 1 M phosphate buffer solution (pH 7.4) and diluted to 100 ppm with 1 M phosphate buffer solution. 1M L-arginine and 1M phosphate buffer solution were mixed at a ratio of 1: 4, and then 80 [mu] l of the solution was dispensed into a 96-well plate. To each sample, 100 μl of 0.01 M aminoguanidine to be used as a positive control and a sample diluted to 100 ppm were added. These samples were mixed well, and finally glucose was added to 1 M phosphate buffer solution so that the final concentration of glucose was 0.1 M, followed by reaction at 70 for 4 hours. The degree of saccharification was measured by measuring the absorbance of the 96-well plate at 420 nm using a spectrophotometer. In the Glycation test group of the following formula (3), 1M L-arginine and 1M glucose were added to induce saccharification. To measure the absorbance of the sample itself, 1M L-arginine and sample alone were added without glucose, Were measured. The saccharide inhibitory activity was calculated using the following Equation 3, and the results are shown in Table 3 below.
[수학식 3]&Quot; (3) "
상기 표 3의 결과에서 볼 수 있듯이, 모르티에렐라 오일은 다른 식물 오일과 비교하였을 때, 보다 우수한 당화 저해율을 보였다. 따라서, 모르티에렐라 오일은 우수한 항당화 효과를 나타내어, 주름 개선 및 항염 등의 활성에 있어 보조적인 역할로 작용하여 상승효과를 기대할 수 있음을 알 수 있었다.As can be seen from the results in Table 3 above, Mortierella oil showed better glycosylation inhibition rates as compared to other plant oils. Therefore, it has been found that Mortierella oil has excellent antihyperglycosylation effect, and acts as an auxiliary agent for improving wrinkles and anti-inflammatory activity, and thus, a synergistic effect can be expected.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all aspects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (10)
Mortierella isabellina ) as an active ingredient.
2. The cosmetic composition according to claim 1, wherein the extract is extracted with at least one solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms, and chloroform.
The cosmetic composition according to claim 1, wherein the cosmetic composition is for enhancing skin elasticity or improving wrinkles.
The cosmetic composition according to claim 1, wherein the cosmetic composition is for improving skin troubles.
The cosmetic composition according to any one of claims 1 to 4, wherein the cosmetic composition has an effect of promoting collagen synthesis, an anti-inflammatory effect, or an anti-glycation effect.
The cosmetic composition according to any one of claims 1 to 4, wherein the cosmetic composition is at least one selected from the group consisting of a solution, an external ointment, a cream, a foam, a nutritional lotion, a softening longevity pack, a pack, Selected from the group consisting of bath salts, sunscreen creams, sun oil, suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays ≪ / RTI > by weight of the composition.
Mortierella isabellina ) as an active ingredient.
The health functional food composition according to claim 7, wherein the health functional food composition is for skin elasticity enhancement, wrinkle improvement, or skin trouble improvement.
Mortierella isabellina ) as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170053742A KR102145032B1 (en) | 2017-04-26 | 2017-04-26 | Cosmetic composition comprising mortierella oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170053742A KR102145032B1 (en) | 2017-04-26 | 2017-04-26 | Cosmetic composition comprising mortierella oil |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200100061A Division KR102243982B1 (en) | 2020-08-10 | 2020-08-10 | Composition for improving skin troubles comprising mortierella oil as an active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180119961A true KR20180119961A (en) | 2018-11-05 |
| KR102145032B1 KR102145032B1 (en) | 2020-08-14 |
Family
ID=64329213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170053742A KR102145032B1 (en) | 2017-04-26 | 2017-04-26 | Cosmetic composition comprising mortierella oil |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102145032B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100313987B1 (en) * | 1991-01-24 | 2001-11-23 | 마르텍 코포레이션 | Microbial oil mixtures and uses thereof |
| KR20100023977A (en) * | 1995-01-03 | 2010-03-04 | 마텍 바이오싸이언스스 코포레이션 | Arachidonic acid-containing oil and methods for the production thereof |
| KR20160095049A (en) * | 2013-12-06 | 2016-08-10 | 디에스엠 아이피 어셋츠 비.브이. | Biomass formulation |
-
2017
- 2017-04-26 KR KR1020170053742A patent/KR102145032B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100313987B1 (en) * | 1991-01-24 | 2001-11-23 | 마르텍 코포레이션 | Microbial oil mixtures and uses thereof |
| KR20100023977A (en) * | 1995-01-03 | 2010-03-04 | 마텍 바이오싸이언스스 코포레이션 | Arachidonic acid-containing oil and methods for the production thereof |
| KR20160095049A (en) * | 2013-12-06 | 2016-08-10 | 디에스엠 아이피 어셋츠 비.브이. | Biomass formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102145032B1 (en) | 2020-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102243982B1 (en) | Composition for improving skin troubles comprising mortierella oil as an active ingredient | |
| KR20180069756A (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR101758144B1 (en) | Composition for anti-aging containing youngia denticulata extract | |
| KR101922089B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR20180090123A (en) | Composition for skin improvement containing liquidambaric lactone | |
| KR20180045626A (en) | Composition for skin improvement containing valechlorine | |
| KR20180027213A (en) | Composition for skin improvement containing Salvianolic acid C | |
| KR102145032B1 (en) | Cosmetic composition comprising mortierella oil | |
| KR20180069755A (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR20180060726A (en) | Composition for skin improvement containing oleandrin | |
| KR20180061662A (en) | Composition for skin improvement containing anemoside A3 | |
| KR20180061663A (en) | Composition for skin improvement containing dehydroevodiamine | |
| KR20180042706A (en) | Composition for skin improvement containing tussilagone | |
| KR20180032029A (en) | Composition for skin improvement containing diosbulbin B | |
| KR20170080082A (en) | Composition for improving skin conditions comprising Polygalaxanthone Ⅲ | |
| KR20170080094A (en) | Composition for improving skin conditions comprising 4-(4-Hydroxyphenyl)-2-butanone | |
| KR20180027214A (en) | Composition for skin improvement containing sinigrin | |
| KR20180027215A (en) | Composition for skin improvement containing swertisin | |
| KR20180042703A (en) | Composition for skin improvement containing corytuberine | |
| KR20180042705A (en) | Composition for skin improvement containing vomicine | |
| KR20180045625A (en) | Composition for skin improvement containing acetylcimigenol arabinoside | |
| KR20180045624A (en) | Composition for skin improvement containing Syringaresnol-4-O-β-D-apiofuranosy | |
| KR20180060729A (en) | Composition for skin improvement containing rehmapicroside | |
| KR20180032030A (en) | Composition for skin improvement containing dracorhodin perochlorate | |
| KR20180061660A (en) | Composition for skin improvement containing thermopsine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant |